AstraZeneca

Total: $105.1 million

Top 3 drugs
Crestor: $32.7 million
Nexium: $29.2 million
Symbicort: $27.8 million
Watch the Crestor TV commercial here >>

AstraZeneca's ($AZN) Crestor remains a substantial seller and doesn't lose its patent in the U.S. until 2016, but it's losing steam nonetheless. Its premium branded drug price gives payers reason to move patients to generic Lipitor, although the company says those defections are stabilizing. U.S. sales fell 4% to $1.4 billion in the first half of the year. U.S. sales of the popular upset stomach drug Nexium held out a bit better but were still off in the first half, down 1% to $1.8 billion. Under a patent settlement with Teva, the company will get generic competition for Nexium next year, and in the meantime, it is fighting a rearguard action against Hanmi Pharmaceutical's modified version, the almost-copycat drug Esomezol, which uses a different salt form than AstraZeneca's pill. Meanwhile, the drugmaker, which has been hacking jobs and making deals to get back to growth, saw U.S. sales of respiratory drug Symbicort, which it also advertised aggressively, jump 24% in H1 2013 to $576 million.

AstraZeneca
Read more on

Suggested Articles

Dogged by opioid liabilities, Mallinckrodt is reportedly looking to restructure its U.S. generics unit to cover its debts and possible settlements.

Novartis has touted early success for its new eye drug Beovu, but an alert tying the drug to potential vision loss might cause docs to balk.

Sanofi will unload six manufacturing sites and 3,100 employees into a new API production company as it looks for €2 billion in cost savings.